A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis

Nephrology Dialysis Transplantation

Volumn 28, Issue 3, 2013, Pages 689-697

  Yao, Ying ^a,b,c   Wang, Su Xia ^a,b,c   Zhang, You Kang ^a,b,c   Qu, Zhen ^a,b,c   Liu, Gang ^a,b,c   Zou, Wan Zhong ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Amyloidosis; Immunoglobulin light chains; Proteinuria; Renal biopsy; Renal insufficiency

Indexed keywords

ALBUMIN; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MELPHALAN; PREDNISONE; URIC ACID;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; ELECTRON MICROSCOPY; FEMALE; GLOMERULONEPHRITIS; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY AMYLOID LIGHT CHAIN AMYLOIDOSIS; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDY; SCORING SYSTEM; URIC ACID BLOOD LEVEL;

AMYLOID; AMYLOIDOSIS; BIOLOGICAL MARKERS; CHINA; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84874879790     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs501     Document Type: Article

References (20)

1. Gertz MA, Lacy MQ, Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 2002; 61: 1-9
2. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458-3471
3. Cohen AD, Comenza RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis and therapy. Hematology Am Soc Hematol Educ Program 2010; 2010: 287-294
4. Eirin A, Irazabal MV, Gertz MA et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular- limited deposition in the kidney. Nephrol Dial Transplant 2012; 27: 1097-1101
5. Gertz MA, Leung N, LacyM Q et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009; 24: 3132-3137
6. Gertz MA. Immunoglobulin light chain amyloidosis: 2012 update on diagnosis, prognosis, and treatment. Am J Hematol 2012; 87: 184-189
7. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328
8. Kumar S, Dispenzieri A, Katzmann JA et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010; 116: 5126-5129
9. Şen S, Sarsik B. A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. Arch Pathol Lab Med 2010; 134: 532-544
10. Larsen CP, Walker PD, Weiss DT et al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 2010; 77: 816-819
11. Bergesio F, Ciciani AM, Santostefano M et al. Renal involvement in systemic amyloidosis - an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant 2007; 22: 1608-1618
12. von Hutten H, Mihatsch M, Lobeck H et al. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol 2009; 33: 1198-1205
13. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59
14. Itabashi M, Takei T, Tsukada M et al. Association between clinical characteristics and AL amyloid deposition in the kidney. Heart Vessels 2010; 25: 543-548
15. Verine J, Mourad N, Desseaux K et al. Clinical and histological characteristics of renal AA amyloidosis: A retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007; 38: 1798-1809
16. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17
17. Osawa Y, Kawamura K, Kondo D et al. Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary AL-type amyloidosis. Clin Exp Nephrol 2004; 8: 127-133
18. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596
19. O'Nuallain B, Hrncic R, Wall JS et al. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 2006; 176: 7071-7078
20. Sethi S, Theis JD, Leung N et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5: 2180-2187